Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $3.75B
• Dividend Yield: N/A
• Average Volume (3M): 763.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.56
• Revenue Growth: -49.51%
• EPS Growth: -44.09%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 71,497,600
• 10 Day Avg. Volume: 991,724
• 30 Day Avg. Volume: 763,256
• PEG Ratio: -0.74
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 64.14
• P/FCF Ratio: -14.56
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 65.56
• Enterprise Value/Gross Profit: 68.76
• Enterprise Value/Ebitda: -10.58
• 1Y Price Target: $63.50
• Price Target Upside: 18.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 57 Neutral
• Price Target: $45.00 ▼(-16.26% Downside)

Kymera Therapeutics' overall stock score reflects a challenging financial performance with persistent losses and valuation concerns. However, the company's strong strategic partnerships and promising clinical advancements provide a positive outlook. Technical indicators suggest neutral momentum, while the earnings call and corporate events highlight significant growth potential.

Positive Factors

Strategic Collaborations

These partnerships could unlock significant milestone payments and expand Kymera's reach in oncology and immuno-inflammatory treatments, enhancing its long-term growth prospects.

Financial Position

A strong cash position ensures Kymera can fund its operations and R&D activities, supporting sustained development and potential commercialization of its drug candidates.

Leadership Change

The appointment of an experienced legal executive can strengthen Kymera's governance and strategic planning, positively impacting its long-term operational efficiency and compliance.

Negative Factors

Revenue Decline

A decline in revenue growth can hinder the company's ability to fund R&D and operational activities, potentially impacting its long-term financial health and market competitiveness.

Operational Challenges

Persistent operational inefficiencies and negative profit margins can strain Kymera's resources, limiting its ability to invest in growth opportunities and achieve sustainable profitability.

Cash Flow Challenges

Negative operating cash flow suggests difficulties in generating sufficient cash from operations, which can affect Kymera's ability to finance its strategic initiatives and maintain financial stability.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive upfront payments, research funding, and milestone payments as its products progress through various stages of development. Additionally, Kymera could earn royalties on future sales of any approved therapies stemming from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its therapeutic candidates in clinical trials and the establishment of strategic alliances to enhance its research capabilities and market reach.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin, the company struggles with negative net income and operational inefficiencies. The balance sheet shows low leverage, but negative returns on equity highlight profitability issues. Cash flow improvements are modest, with ongoing challenges in generating positive operating cash flow.

Income Statement

Kymera Therapeutics has experienced declining revenue growth, with a significant drop of 24.07% in the TTM period. The company maintains a high gross profit margin of 95.34%, indicating efficient cost management. However, the net profit margin is deeply negative at -6.16%, reflecting substantial losses. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company has a low debt-to-equity ratio of 0.09, suggesting conservative leverage. However, the return on equity is negative at -31.60%, indicating that the company is not generating positive returns for shareholders. The equity ratio is relatively stable, showing a solid equity base compared to total assets.

Cash Flow

Kymera Therapeutics shows a slight improvement in free cash flow growth at 5.40% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.71M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	42.63M	47.07M	78.59M	43.85M	70.44M	-28.07M
EBITDA	-277.16M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-275.43M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet
Total Assets	1.13B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	665.45M	488.74M	374.88M	559.49M	567.61M	458.73M
Total Debt	85.71M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	159.59M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	971.48M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-252.92M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-251.01M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	19.52M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	499.67M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 53.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Positive. The current price of 53.74 is above the 20-day moving average (MA) of 46.43, above the 50-day MA of 44.48, and above the 200-day MA of 38.75, indicating a bullish trend. The MACD of 2.51 indicates Negative momentum. The RSI at 71.92 is Negative, neither overbought nor oversold. The STOCH value of 95.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AKRO	60 Neutral	3.80B	-12.16	―	―	―	-11.39%
PTGX	60 Neutral	4.10B	90.79	40.75%	―	-34.45%	-69.75%
KYMR	57 Neutral	$3.75B	―	-33.26%	―	-49.51%	-44.09%
CRNX	52 Neutral	3.31B	-8.73	-22.52%	―	―	-9.10%
APLS	47 Neutral	2.87B	-12.18	-86.58%	―	20.02%	33.45%
MLTX	41 Neutral	3.46B	-20.21	―	―	―	-208.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Announces New Chief Legal Officer

On September 3, 2025, Kymera Therapeutics announced the retirement of Ellen Chiniara as Chief Legal Officer, with Brian R. Adams succeeding her. This leadership change is part of Kymera’s strategic efforts to advance its novel programs in the field of immunology, aiming to redefine treatment possibilities with groundbreaking oral medicines.

Kymera Therapeutics Announces Public Offering to Raise Funds

On June 26, 2025, Kymera Therapeutics announced an underwritten public offering of its common stock and pre-funded warrants, expected to raise approximately $237.3 million, with the potential to increase to $272.7 million if underwriters exercise their options fully. The proceeds will be used to advance Kymera’s clinical and preclinical degrader programs and for general corporate purposes. The offering is anticipated to close on June 30, 2025, subject to customary conditions, and is part of Kymera’s strategy to fund operations into mid-2028.

Kymera Therapeutics Holds Annual Shareholder Meeting

On June 25, 2025, Kymera Therapeutics held its Annual Meeting of Shareholders, where three key proposals were voted on. Shareholders elected Jeffrey Albers and Felix J. Baker as Class II directors for a three-year term, approved the compensation of named executive officers on a non-binding basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Kymera Therapeutics Partners with Gilead for Oncology Treatment

On June 25, 2025, Kymera Therapeutics announced an exclusive option and license agreement with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatment, including breast cancer. The agreement could bring Kymera up to $750 million in payments and royalties, with Kymera leading research activities. This collaboration aims to advance cancer treatment by selectively targeting and degrading disease-driving proteins, potentially improving care for patients with high unmet medical needs.

Kymera Therapeutics Advances KT-485 in Sanofi Collaboration

On June 25, 2025, Kymera Therapeutics announced an update on its collaboration with Sanofi, highlighting the advancement of KT-485, an oral IRAK4 degrader, into clinical studies for immuno-inflammatory diseases. This decision, which includes a $20 million milestone achievement for Kymera, marks a strategic shift from KT-474 to KT-485, reflecting its superior preclinical profile and potential to transform immunology treatments. The collaboration could yield up to $975 million in clinical, regulatory, and commercial milestones, positioning Kymera strongly in the biopharmaceutical industry.